momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (11713)	10/2/2018 12:31:19 AM
From: scaram(o)uche	of 12215

>> efficacy drops off after treatment << Yes, the chances of that were 100%. Not 99%. Not some undefined percentage. Known decades before a SARM was a SARM. >> So if they are being serious, should they drop this program, and deploy their resources elsewhere? << Why? My mom never got back on her feet, despite physical therapy, after five days of hospitalization. She died soon thereafter. I haven't seen mention of any sudden toxic reaction to 5211, perhaps there is room to explore additional indications. >> They state their trial was not powered for significance on this endpoint. LMAO! << Walk tests have large standard deviations. And this trial mixed guys like me in with postmenopausal types with osteoporosis. I notice that he/she/it chooses not to highlight triglycerides. Nor did h/s/i point to "Hormone levels and lipids returned to baseline after treatment discontinuation." Last, you get the feeling that h/s/i doesn't know that LGD-4033 *is VK5211??

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next